FB-610 is under clinical development by 1St Bio Therapeutics and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FB-610’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FB-610 overview

FB-610 is under development for the treatment of Parkinson’s disease and amyotrophic lateral sclerosis. It is a benzothiazol derivative and acts by targeting c-Abl protein. It is administered through oral route.

1St Bio Therapeutics overview

1st Bio Therapeutics (1st Bio) is a healthcare company that provide treatment for degenerative brain diseases. The company is headquartered in Seongnam-si, Gyeonggi-do, South Korea.

For a complete picture of FB-610’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.